|
07/12/2016 |
NGcGM3/VSSP in small cell lung cancer |
CIM |
Registered outdated |
|
15/11/2016 |
EC122 HER-1 Prostate Phase I |
CIM |
Registered |
|
07/12/2016 |
NGcGM3/VSSP in Metastatic melanoma |
CIM |
Registered |
|
05/11/2013 |
RituxCIM in relapsed or refractory indolent B-cell non-Hodgkin lymphoma |
CIM |
Registered outdated |
|
23/05/2014 |
Phase II / III. Nimotuzumab in patients with triple-negative breast cancer. |
CIM |
Registered |
|
12/10/2016 |
NGcGM3/VSSP and nimotuzumab in patients with triple negative breast cancer |
CIM |
Registered |
|
22/11/2013 |
hR3 in metastatic or recurrent colorectal cancer |
CIM |
Registered |
|
26/05/2014 |
Racotumomab,Nimotuzumab or Docetaxel in the treatment of the advanced non-small cell lung cancer. |
CIM |
Registered |
|
05/08/2014 |
CIMAVax EGF in Lung Cancer in PHC. Phase IV |
CIM |
Registered |
|
22/05/2015 |
Itolizumab for Relapsing Remitting Multiple Sclerosis |
CIM |
Registered |
|
29/01/2016 |
Predictor of response with CIMAvax EGF© in NSCLC Phase III |
CIM |
Registered |
|
08/10/2015 |
Itolizumab for Moderate-to-Severe Psoriasis-phase 3 |
CIM |
Registered |
|
23/12/2016 |
Itolizumab (T1h) combined with insulin in patients with Type I Diabetes Mellitus |
CIM |
Registered |
|
08/07/2015 |
Racotumomab-alum for recurrent platimun-sensitive epithelial ovarian cancer |
CIM |
Registered |
|
15/12/2015 |
Racotumomab-alum cancer vaccine for solid tumors in pediatric patients |
CIM |
Registered |
|
05/09/2017 |
CIMAbior® in CD20-positive B-cell Non-Hodgkin Lymphoma |
CIM |
Registered |
|
15/12/2015 |
Vaxira as adjuvant treatment for non-small cell lung cancer |
CIM |
Registered outdated |
|
22/04/2016 |
NAcGM3/VSSP-aids-patients drug resistant to antiretroviral treatment-Phase I-II |
CIM |
Registered |
|
04/12/2015 |
Dose scale-up and cohort expansion with the therapeutic mAb 14F7 |
CIM |
Registered outdated |
|
30/06/2016 |
Nimotuzumab inoperable esophageal epithelial tumors, Phase IV |
CIM |
Registered |
